Status:
COMPLETED
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Heart Failure
Eligibility:
All Genders
18-100 years
Brief Summary
This was a non-interventional, retrospective EMR analysis of longitudinal prescriptions in India for a period of 1.5 years. Demographic profile of patients with heart failure with reduced ejection fra...
Detailed Description
Index date was date of 1st prescription of sacubitril/valsartan. Dose titration of sacubitril/valsartan was assessed for a period of 6 months post index date.
Eligibility Criteria
Inclusion
- Patients ≥18 years with a diagnosis of HFrEF as mentioned in database or heart failure with a recording of LVEF \<40% at or before the index date
- A prescription of sacubitril/valsartan
Exclusion
- Diagnosis of HF specified as preserved/mid-range ejection fraction
Key Trial Info
Start Date :
October 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT04735354
Start Date
October 27 2020
End Date
June 1 2022
Last Update
May 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational Site
Mumbai, India